These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22406532)

  • 1. Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.
    Song WL; Stubbe J; Ricciotti E; Alamuddin N; Ibrahim S; Crichton I; Prempeh M; Lawson JA; Wilensky RL; Rasmussen LM; Puré E; FitzGerald GA
    J Clin Invest; 2012 Apr; 122(4):1459-68. PubMed ID: 22406532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Impact In Vivo of Pf4-ΔCre-Mediated and Gp1ba-ΔCre-Mediated Depletion of Cyclooxygenase-1 in Platelets in Mice.
    Tang SY; Lordan R; Meng H; Auerbach BJ; Hennessy EJ; Sengupta A; Das US; Joshi R; Marcos-Contreras OA; McConnell R; Grant GR; Ricciotti E; Muzykantov VR; Grosser T; Weiljie AM; FitzGerald GA
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1393-1406. PubMed ID: 38660804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis.
    Strack AM; Carballo-Jane E; Wang SP; Xue J; Ping X; McNamara LA; Thankappan A; Price O; Wolff M; Wu TJ; Kawka D; Mariano M; Burton C; Chang CH; Chen J; Menke J; Luell S; Zycband EI; Tong X; Raubertas R; Sparrow CP; Hubbard B; Woods J; O'Neill G; Waters MG; Sitlani A
    J Lipid Res; 2013 Jan; 54(1):177-88. PubMed ID: 23103473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
    Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
    Lauring B; Dishy V; Luo WL; Laterza O; Patterson J; Cote J; Chao A; Larson P; Gutierrez M; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Dec; 49(12):1426-35. PubMed ID: 19833861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.
    Cheng K; Wu TJ; Wu KK; Sturino C; Metters K; Gottesdiener K; Wright SD; Wang Z; O'Neill G; Lai E; Waters MG
    Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6682-7. PubMed ID: 16617107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse.
    McClelland S; Gawaz M; Kennerknecht E; Konrad CS; Sauer S; Schuerzinger K; Massberg S; Fitzgerald DJ; Belton O
    Atherosclerosis; 2009 Jan; 202(1):84-91. PubMed ID: 18514659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans.
    Song WL; Wang M; Ricciotti E; Fries S; Yu Y; Grosser T; Reilly M; Lawson JA; FitzGerald GA
    J Biol Chem; 2008 Jan; 283(2):1179-88. PubMed ID: 17993463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice.
    Babaev VR; Ding L; Reese J; Morrow JD; Breyer MD; Dey SK; Fazio S; Linton MF
    Circulation; 2006 Jan; 113(1):108-17. PubMed ID: 16380543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
    Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
    J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin D2 mediates neuronal protection via the DP1 receptor.
    Liang X; Wu L; Hand T; Andreasson K
    J Neurochem; 2005 Feb; 92(3):477-86. PubMed ID: 15659218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction.
    Tailor A; Wood KC; Wallace JL; Specian RD; Granger DN
    Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3636-42. PubMed ID: 17933963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice.
    Popp L; Häussler A; Olliges A; Nüsing R; Narumiya S; Geisslinger G; Tegeder I
    Eur J Pain; 2009 Aug; 13(7):691-703. PubMed ID: 18938093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cyclooxygenase-1 and -2 in endothelium-dependent contraction of atherosclerotic mouse abdominal aortas.
    Li S; Liu B; Luo W; Zhang Y; Li H; Huang D; Zhou Y
    Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):67-74. PubMed ID: 26444418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain.
    Cao X; Peterson JR; Wang G; Anrather J; Young CN; Guruju MR; Burmeister MA; Iadecola C; Davisson RL
    Hypertension; 2012 Apr; 59(4):869-76. PubMed ID: 22371360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of prostacyclin in the cardiovascular response to thromboxane A2.
    Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
    Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Consequences of Prostanoid I Receptor Deletion in Microsomal Prostaglandin E Synthase-1-Deficient Hyperlipidemic Mice.
    Tang SY; Monslow J; R Grant G; Todd L; Pawelzik SC; Chen L; Lawson J; Puré E; FitzGerald GA
    Circulation; 2016 Jul; 134(4):328-38. PubMed ID: 27440004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.